PETCT Imaging Using 68Ga18F-PentixaforPentixather to Detect Primary and Metastatic Lesions in CXCR4-Related Diseases

What this Trial Is About

Researchers are evaluating the usefulness of 68Ga18F-PentixaforPentixather PETCT imaging for diagnosing primary and metastatic lesions in patients with various CXCR4-related diseases. The study aims to assess how well this imaging method detects disease sites by measuring lesion uptake and calculating diagnostic accuracy measures such as sensitivity, specificity, and predictive values. Participants receive a single intravenous injection of 2-5 mCi of the radiotracer 68Ga18F-PentixaforPentixather, followed by PETCT imaging to visualize lesions. This procedure is used either for initial disease assessment or to detect recurrence. The imaging results are quantified using the maximum standardized uptake value SUVmax. During the study, participants undergo PETCT scans and have their lesion uptake measured. Researchers evaluate the standardized uptake value after 30 days, along with the diagnostic effectiveness of the imaging method. The study includes patients aged 18 to 80 years with suspected or confirmed untreated CXCR4-related diseases, and participation may include healthy volunteers. Safety and allergy monitoring are also part of the study process.

Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases